Regeneron Pharmaceuticals Inc

REGNNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
614.73 USD
↘ 0.25 (0.04%)AT CLOSE (11:59 AM EDT)
611.85
↘ 2.88 (0.47%)
POST MARKET (AS OF 06:10 PM EDT)
Post Market
AS OF 06:10 PM EDT
611.85
↘ 2.88 (0.47%)
🟢Market: OPEN

Regeneron Pharmaceuticals Inc (REGN) trades at $614.68 per share. The technical outlook is "Sell" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, REGN appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Jun 16, 2026.

Open?$615.18
High?$617.60
Low?$608.21
Prev. Close?$614.98
Volume?1.0M
Avg. Volume?1.1M
VWAP?$613.77
Rel. Volume?0.93x
Bid / Ask
Bid?$579.50 × 40
Ask?$639.08 × 40
Spread?$59.58
Midpoint?$609.29
Valuation & Ratios
Market Cap?64.5B
Shares Out?103.0M
Float?98.3M
Float %?94.6%
P/E Ratio?14.58
P/B Ratio?2.05
EPS?$42.19
Dividend?0.58%
Ex-Dividend?N/A
News
Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
15.4K
Market Cap
64.2B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.regeneron.com
Listed
1991-04-02
Address
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
Phone: (914) 847-7000
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
100
Momentum?
45
Short Sent.?
70
Piotroski F-Score?4/9Mixed
Altman Z-Score?6.39Safe
Confidence?66%Moderate
Full Fundamental Analysis →
Short InterestLow
Short % of Float?3.05%Low
Short Interest?3.0M
Days to Cover?2.0
Free Float98.3M
Avg Daily Volume1.5M
Settlement Date2026-05-29
Financial Health
Current Ratio?3.57Strong
Quick Ratio?2.96Strong
Cash Ratio?0.58Adequate
Debt/Equity?0.09Low
ValuationATTRACTIVELY VALUEDvs 10 peers + S&P 500
Score
83/100
P/E?
Peers
100
S&P
82
14.6CHEAP▾
P/B?
Peers
80
S&P
73
2.05CHEAP▾
P/S?
Peers
82
S&P
35
4.32FAIR▾
P/FCF?
Peers
75
S&P
72
15.7CHEAP▾
EV/EBITDA?
Peers
63
S&P
47
15.4FAIR▾
EV/Sales?
Peers
91
S&P
43
4.30FAIR▾
Returns & Efficiency
ROE?
Peers
29
S&P
51
14.1%STRONG▾
ROA?
Peers
63
S&P
77
10.8%STRONG▾
Cash Flow & Enterprise
FCF?$4.1B
Enterprise Value?$64.2B
Fundamentals ratios updated end of day
MarketsMoversWatchlist